Terms: = Thyroid cancer AND TSC2, FLJ43106, 7249, ENSG00000103197, LAM, tuberin, TSC4 AND Treatment
6 results:
1. Identification of a Novel tsc2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma.
Zheng X; Wang J; Ye T; Tang W; Pan X; Wang S; Liu J
Endocrine; 2023 Sep; 81(3):540-546. PubMed ID: 37219702
[TBL] [Abstract] [Full Text] [Related]
3. The pleura and the endocrine system.
Sorino C; Negri S; Spanevello A; Feller-Kopman D
Eur J Intern Med; 2020 Feb; 72():34-37. PubMed ID: 31918926
[TBL] [Abstract] [Full Text] [Related]
4. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
[TBL] [Abstract] [Full Text] [Related]
5. mTOR activation is critical for betulin treatment in renal cell carcinoma cells.
Cheng W; Ji S; Zhang H; Han Z; Liu Q; Wang J; Ping H
Biochem Biophys Res Commun; 2017 Jan; 482(4):1030-1036. PubMed ID: 27908730
[TBL] [Abstract] [Full Text] [Related]
6. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.
Han B; Cui H; Kang L; Zhang X; Jin Z; Lu L; Fan Z
Tumour Biol; 2015 Aug; 36(8):6295-304. PubMed ID: 25854169
[TBL] [Abstract] [Full Text] [Related]